Ninti Hospital is building a need-driven, specialty-led healthcare network — anchored in operational single-super-specialty cardiac centres in tier-2/3 Bihar, extending to multi-specialty hospitals in Patna and Lucknow, and culminating in a flagship onco-focused super-specialty hospital in Delhi NCR.
Ninti Hospital is a healthcare network under construction — combining operational single-super-specialty cardiac centres, multi-specialty hospitals under build-out, and a proposed flagship onco-focused super-specialty hospital in Delhi NCR. The network is designed to address India's acute healthcare infrastructure gap: with bed density at 1.42 per 1,000 vs the WHO benchmark of 3.0, and doctor density at 0.86 vs 1.0.
Ninti's current footprint includes Saharsa Cardiac Care (50 beds, operational, broke even September 2024), Muzaffarpur Cardiac Care (broke even September 2024), and Patna Mother Care (100 beds, infrastructure ready). The expansion roadmap adds Purnea (100 beds, 2026), Patna Multispecialty (200 beds, 2027), Lucknow Multispecialty (200 beds, 2027), and the flagship Delhi NCR Onco-focused Super-Specialty Hospital (350 beds, 2029) — taking network capacity to approximately 1,000 beds.
The Delhi NCR project is the pitch: a INR 219 Crore project positioned to capture the Indian oncology market (projected INR 2.5 trillion by 2027) with Delhi NCR cancer incidence rising 23% by 2026. The financial model projects EBITDA breakeven in Year 3, first positive PAT in Year 4, and 30% PAT margin by Year 10 on INR 1,334 Cr of revenue.
Mission: improve the quality of life for patients through empathetic, affordable, and comprehensive medical care. Vision: establish dedicated super-specialty hospitals using innovative and specialised technology, delivering exceptional value to patients and all stakeholders.
Ninti's operating model is deliberately specialty-led, not general-hospital-led. Single-super-specialty cardiac centres in tier-2/3 Bihar (Saharsa, Muzaffarpur, Purnea) bring advanced cardiac care — cath labs, CTVS OT, CCU, angioplasty — directly to underserved populations at 24×7 availability. These flagship specialty centres then serve as anchor points for multi-specialty expansion into Patna and Lucknow. The Delhi NCR project represents the apex of the model: a 350-bed onco-focused super-specialty hospital with full cardiology, neurology, and orthopaedics.
The network is differentiated on five value-chain axes: operational efficiency (cloud-based HIS, lean staffing); technology adoption (IT planning led by a medical-doctor / digital-transformation CTO); community engagement (need-based tier-2/3 siting); partnerships (medical tourism agencies, insurance panels); and employee engagement (HR led by a 13-year Apollo / North East India veteran).
The Indian healthcare market is projected to grow from USD 108.57 billion (2024) to USD 197.31 billion (2030), a 10.64% CAGR driven by government policy (Ayushman Bharat, healthcare expenditure reaching 2.5% of GDP), telemedicine and digital health expansion, and medical tourism with India's competitive pricing attracting international patients.
The cancer opportunity is particularly acute. India has ~25 lakh people living with cancer, ~7 lakh new cases annually, and projected new-case growth of 13% over 5 years (from 13.9L to 15.7L new cases 2020–2025). The top incidence sites are Lip/Oral Cavity (16%), Lung (9%), Oesophagus (7%), Colorectum (6%), Stomach (6%), and Prostate (5%).
India suffers a structural shortage: 1.42 beds per 1,000 vs WHO threshold of 3.0; 0.86 doctors per 1,000 vs WHO of 1.0. India needs 2.9M more beds by 2030 (1.3B sq ft of healthcare real estate) to achieve 2.0 beds per 1,000. Private sector is already 70% of existing bed stock, and 30,000+ beds are being added by private players over the next 5 years.
| Project Cost Component | INR Cr |
|---|---|
| Leasehold Improvement | 3.00 |
| Medical Equipments | 150.00 |
| Other Fixed Assets (incl. IT) | 7.00 |
| Sub-Total (A) | 160.00 |
| Pre-Operative Expenses | 1.00 |
| Contingencies | 8.00 |
| Sub-Total (B) | 9.00 |
| Operational Loss (gestation) | 48.00 |
| Working Capital Margin | 2.00 |
| Sub-Total (C) | 50.00 |
| Total Project Cost (A+B+C) | 219.00 |
The Delhi NCR super-specialty facility offers comprehensive cancer care — Diagnostic Services, Advanced Imaging, Bone Marrow Transplant (BMT), Chemotherapy, Medical Oncology, and Surgical Oncology — plus Cardiology, Neurology, and Orthopaedics.
Technology stack includes Image-Guided Radiotherapy for precision radiation, Radiation Therapy suites, Infusion Centres, and specialised Operating Theatres. The oncology clinical team includes Dr. Rajesh Jain (Director, 25+ years surgical oncology), Dr. Shruti Bhatia (Principal, Gynae Oncology), Dr. Ishan Mohan (Consultant, Surgical Oncology — MCh Tata Memorial), and Dr. Pranjal Kulshreshtha (Consultant, Surgical Oncology).
The hospital is designed for patient-first personalised treatment — treatment plans tailored to each patient's genetic and clinical profile, with Outpatient services to reduce hospital stays, and dedicated programs for medical tourism given India's cost competitiveness for international patients.
| INR Cr | Y1 | Y2 | Y3 | Y4 | Y5 | Y7 | Y10 |
|---|---|---|---|---|---|---|---|
| Revenue | 145 | 313 | 468 | 649 | 809 | 1,064 | 1,334 |
| Gross Contribution | 68 | 160 | 243 | 344 | 437 | 596 | 800 |
| Gross Margin | 47% | 51% | 52% | 53% | 54% | 56% | 60% |
| EBITDA | (33) | 25 | 87 | 175 | 255 | 387 | 553 |
| EBITDA Margin | -23% | 8% | 19% | 27% | 32% | 36% | 41% |
| PAT | (84) | (19) | 49 | 112 | 167 | 268 | 394 |
| PAT Margin | -58% | -6% | 10% | 17% | 21% | 25% | 30% |
Flagship onco-focused super-specialty hospital in Delhi NCR — 350 beds, 30-month construction, COD Month 31. Full oncology suite: surgical, medical, radiation, gynae; BMT; IGRT; PET-CT. 99.93% debt-funded (INR 218.85 Cr @ 6%). Projected Y4 first positive PAT (INR 112 Cr), Y10 revenue INR 1,334 Cr at 41% EBITDA · 30% PAT margin · INR 1,961 Cr closing cash. Cardiac-centre breakeven proof points already validated in Bihar.
Year-by-year P&L, balance sheet, working capital, and SWOT deep-dive available under separate password.